Literature DB >> 19602918

Prostate specific antigen in women with menstrual disturbances and fibrocystic mastopathy.

S Radowicki1, M Kunicki.   

Abstract

The objective of this study was to evaluate serum prostate specific antigen (PSA) levels in women with menstrual disturbances and fibrocystic mastopathy. A total of 114 women with fibrocystic breast disease with cysts <10 mm (group I), 62 with macrocysts >10 mm (group II) and 46 healthy volunteers, who served as control subjects, were recruited for this prospective study. Each patient underwent complete gynecological examination and had performed sonography of the breasts. Moreover menstrual pattern, serum levels of free and total PSA, LH, FSH, SHBG, PRL, estradiol, progesterone, TSH, T4, as well as serum total testosterone, were evaluated in each subject. We compared serum free and total PSA levels between women with different menstrual pattern within groups of women with micro- and macrocysts. We also evaluated correlations between serum free and total PSA and hormonal/descriptive variables. We found that, in group II, women with regular menses and polymenorrhea revealed significantly higher serum free PSA than women with oligomenorrhea and secondary amenorrhea. Moreover, we found a positive correlation between serum total testosterone and total PSA in the control group and between progesterone and total PSA in group II. Our data show that serum free PSA is increased in women with regular menstrual cycles and polymenorrhea. This later relationship refers to women with macrocysts. Further studies are required to clarify the relationships between serum PSA and menstrual disturbances in women with mastopathy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19602918     DOI: 10.1007/BF03345752

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

Review 1.  Hyperprolactinemic disorders.

Authors:  E Katz; E Y Adashi
Journal:  Clin Obstet Gynecol       Date:  1990-09       Impact factor: 2.190

2.  Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women.

Authors:  C Negri; F Tosi; R Dorizzi; A Fortunato; G G Spiazzi; M Muggeo; R Castello; P Moghetti
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

Review 3.  Benign breast diseases: classification, diagnosis, and management.

Authors:  Merih Guray; Aysegul A Sahin
Journal:  Oncologist       Date:  2006-05

4.  Changes of PSA concentrations in serum and saliva of healthy women during the menstrual cycle.

Authors:  Hülya Aksoy; Fatih Akçay; Zühal Umudum; A Kadir Yildirim; Ramazan Memisogullari
Journal:  Ann Clin Lab Sci       Date:  2002       Impact factor: 1.256

5.  Breast tissues in transsexual women--a nonprostatic source of androgen up-regulated production of prostate-specific antigen.

Authors:  V H Goh
Journal:  J Clin Endocrinol Metab       Date:  1999-09       Impact factor: 5.958

6.  Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone.

Authors:  J Adams; S Franks; D W Polson; H D Mason; N Abdulwahid; M Tucker; D V Morris; J Price; H S Jacobs
Journal:  Lancet       Date:  1985 Dec 21-28       Impact factor: 79.321

7.  Fibrocystic breast disease: pathophysiology, pathomorphology, clinical picture, and management.

Authors:  H Vorherr
Journal:  Am J Obstet Gynecol       Date:  1986-01       Impact factor: 8.661

Review 8.  Fibrocystic changes.

Authors:  J V Fiorica
Journal:  Obstet Gynecol Clin North Am       Date:  1994-09       Impact factor: 2.844

9.  The "luteal breast": hormonal and sonographic investigation of benign breast disease in patients with cyclic mastalgia.

Authors:  J W Ayers; G P Gidwani
Journal:  Fertil Steril       Date:  1983-12       Impact factor: 7.329

10.  Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer.

Authors:  N Zarghami; L Grass; E P Diamandis
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  1 in total

1.  Prostate specific antigen and mastopathy.

Authors:  V Wiwanitkit
Journal:  J Endocrinol Invest       Date:  2010-06       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.